Yoshio Fukuda

This inventor holds 12 USPTO granted patents, plus 1 CIPO patent and 3 EPO patents. Top assignees: Eisai Company, Limited, Eisai R&d Management Co., Ltd., Mercian Corporation. Active years: 1995-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yoshio Fukuda. Retrieved from https://idiyas.com/inventor/yoshio-fukuda

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12

% Patents Active = 75.0

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 1)

Average Co-Inventor Count = 10.4

ph-index = 6

Forward Citations = 272(Granted Patents)

Location History:

Tsukuba, JP (2006 - 2009)
Ibaraki, JP (1995 - 2011)

Company Filing History:

7 out of 677

Eisai Company, Limited

patents

5 out of 530

Eisai R&d Management Co., Ltd.

where one patent can have more than one assignee

Years Active: 1995-2011

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7893068 - Physiologically active substances (2011-02-22),

2. 7619100 - Physiologically active substances (2009-11-17),

3. 7612092 - Nitrogen-containing aromatic derivatives (2009-11-03),

4. 7550503 - Physiologically active substances (2009-06-23),

5. 7468380 - Nitrogen-containing aromatic derivatives (2008-12-23),

6. 7256178 - Physiologically active substances (2007-08-14),

7. 7253286 - Nitrogen-containing aromatic derivatives (2007-08-07),

8. 7109219 - Nitrogen-containing aromatic derivatives (2006-09-19),

9. 6051705 - Substituted thiazolo[3,2-a]azepine derivatives (2000-04-18),

10. 5789403 - Substituted thiazolo �3,2-a!azepine derivatives (1998-08-04),

11. 5719303 - Phosphonic acid derivatives (1998-02-17),

12. 5453524 - Phosphorus-containing isoprenoid derivatives (1995-09-26),

Title: The Innovative Work of Inventor Yoshio Fukuda

Introduction:

Yoshio Fukuda, a prolific inventor based in Tsukuba, Japan, has made significant contributions to the field of pharmaceuticals and cancer research. With a remarkable portfolio of 12 patents, Fukuda's work has been pivotal in developing physiologically active substances with implications for cancer treatment.

Latest Patents:

Fukuda's latest patents focus on physiologically active substances that have shown promise in suppressing angiogenesis and VEGF production in hypoxic conditions, particularly in the treatment of solid cancers. The compounds he has developed demonstrate unique efficacy as therapeutic agents for combating cancer growth.

Career Highlights:

Throughout his career, Yoshio Fukuda has been associated with prominent companies in the pharmaceutical industry, including Eisai Company, Limited, and Eisai R&D Management Co., Ltd. His work within these organizations has been instrumental in driving forward innovative research and development initiatives aimed at addressing critical medical needs.

Collaborations:

Fukuda has collaborated closely with esteemed colleagues such as Tomohiro Matsushima and Akihiko Tsuruoka. Together, they have synergized their expertise to advance groundbreaking discoveries in the realm of physiologically active substances and their applications in cancer therapeutics.

Conclusion:

Inventor Yoshio Fukuda's groundbreaking research and patented inventions exemplify his dedication to advancing pharmaceutical innovation, particularly in the crucial area of cancer treatment. His contributions hold profound potential for revolutionizing therapeutic approaches and improving patient outcomes in the fight against cancer.

Profile summary based on public USPTO records.